Condition

Advanced Bladder Carcinoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 2 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting1

Common interventions11

Lead sponsors shown2

Clinical trials

2 shown

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced CancerNCT05969860 · 2023-08-23

RECRUITING

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesNCT04902040 · 2021-04-14

TERMINATED

Common interventions

AtezolizumabBIOLOGICAL1 AvelumabDRUG1 Clinical EncounterPROCEDURE1 DurvalumabBIOLOGICAL1 Home Health EncounterOTHER1 NivolumabBIOLOGICAL1 PembrolizumabBIOLOGICAL1 PlinabulinDRUG1 Quality-of-Life AssessmentOTHER1 Questionnaire AdministrationOTHER1 Radiation TherapyRADIATION1

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

avelumab1

Leading sponsors

M.D. Anderson Cancer Center 1 Mayo Clinic 1

Trial status mix

RECRUITING1

TERMINATED1

Phase mix

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.